Hybridon Announces Oral Presentation of Results for Phase I Trial of IMOxine(R) at ASCO 2005
16 Mayo 2005 - 8:35AM
PR Newswire (US)
Hybridon Announces Oral Presentation of Results for Phase I Trial
of IMOxine(R) at ASCO 2005 -- Hybridon Plans New Chemotherapy
Combination Study in Non-Small Cell Lung Cancer -- CAMBRIDGE,
Mass., and WASHINGTON, May 16 /PRNewswire-FirstCall/ -- Hybridon,
Inc. (AMEX:HBY) announced that it and the Lombardi Comprehensive
Cancer Center (LCCC) at Georgetown University Hospital today
presented Phase I results of a study on IMOxine(R), Hybridon's lead
agonist of Toll-like receptor 9, at ASCO 2005. The results were
given in an oral presentation titled "Phase I Trial of Escalating
Doses of the TLR9 Agonist HYB2055 in Patients with Advanced Solid
Tumors" (Abstract #2503). IMOxine is currently in a Phase II
single-agent study in patients with renal cell carcinoma. The
presentation was made by Daniel Moore, M.D. of the Lombardi
Comprehensive Cancer Center (LCCC), Georgetown University in the
session of Developmental Therapeutics: Immunotherapy. Dr. Moore was
honored by ASCO as a Merit Award recipient for the IMOxine
presentation. "IMOxine is a promising cancer compound that was well
tolerated in patients and showed immunopharmacological activity in
the phase I trial," said John L. Marshall, M.D., Director,
Developmental Therapeutics and Associate Professor of Medicine at
LCCC. "We are excited about Hybridon's plans to initiate a new
Phase I/II study in patients with non-small cell lung cancer
(NSCLC) using IMOxine in combination with an established
chemotherapy regimen as front-line treatment. This NSCLC trial will
be conducted here at Georgetown with Dr. Shakun Malik as Principal
Investigator." "The Phase I results are a strong start to our
development strategy for IMOxine. One Phase I patient remains on
IMOxine treatment showing continued immune response of white blood
cells to weekly treatment through at least 48 weeks as well as long
term safety," said Tim Sullivan, Vice President of Development
Programs at Hybridon. "We anticipate expansion into multiple
clinical trials in the coming months, starting with the NSCLC trial
with Dr. Marshall's group. We also are seeking collaborations with
companies to initiate additional combination trials." About the
Phase I Oncology Trial The trial was designed to evaluate the
safety and immunologic activity of IMOxine as a monotherapy in
patients with refractory solid tumors that had been classified as
progressive disease in spite of multiple courses of prior
therapies. IMOxine was administered as a monotherapy once a week by
subcutaneous injection at dosages of 0.04, 0.16, 0.32, 0.48, or
0.64 mg/kg/week. Treatment duration is open-ended, based on safety
and radiology assessment of tumor status at 8-week intervals.
Nineteen of 23 patients completed at least four consecutive weeks
of treatment to fulfill the safety evaluation requirements of the
protocol. IMOxine induced immunological activity as shown by
hematology and flow cytometry parameters such as lymphocyte
mobilization and increases in serum cytokines including IL-12.
Although data from a Phase I oncology trial are highly dependent on
baseline patient status, many of the immunology results indicate
the possibility of a bell-shaped dose response curve over the range
of 0.04 to 0.64 mg/kg/week. Seventeen patients were assessed for
disease status by radiology and clinical evaluation after eight
weeks of treatment, and nine of these patients were determined to
have stable disease. One patient with metastatic renal cell
carcinoma has maintained stable disease through the Week 56
evaluation and continues on treatment. Adverse effects have been
consistent with the expected immune stimulation activity of
IMOxine, and primarily have been mild to moderate injection site
reactions of erythema and induration, pain, and "flu-like" symptoms
(rigors/chills, fever, nausea, myalgia, headache, malaise, and
fatigue). Observations that were considered serious adverse events
and possibly related to IMOxine treatment have been: transient
hypoxia, dyspnea, and rigors/chills 1 hour post-dose (1 patient);
abdominal pain with nausea/vomiting (1 patient); and anemia
requiring transfusion (2 patients). About IMOxine IMOxine is
Hybridon's a 2nd-generation immune modulatory oligonucleotide
(IMO(TM)) that functions as an agonist of Toll-like Receptor 9
(TLR9), a specific protein receptor in certain cells of the immune
system. Other receptors also may play a role in the immune system
response to IMOxine. TLR9 has been shown to recognize bacterial DNA
and induce a defensive immune response, producing a Th1-type
cytokine profile that allows modulation of host dendritic cells and
B lymphocytes. IMOxine and its murine analogue have been studied in
a variety of preclinical tumor models, as monotherapy and in
combinations with selected chemotherapeutic agents and monoclonal
antibodies, and with radiation. IMOxine (also known as HYB2055 for
Injection) is currently in a Phase II, multi-center, open label
monotherapy study in patients with metastatic or recurrent clear
cell renal carcinoma. About Hybridon Hybridon, Inc. is developing
novel therapeutics based on synthetic nucleic acid chemistry for
the treatment of cancer, asthma/allergies, and infectious diseases.
Hybridon's proprietary IMO drug candidates are designed to modulate
immune responses through Toll-like receptors, the body's first line
of defense against disease. The Company's nucleic acid chemistry
expertise has also generated a portfolio of partnered products and
intellectual property, creating the potential for long-term value
for Hybridon. For more information please visit our website at
http://www.hybridon.com/. This press release contains
forward-looking statements concerning Hybridon that involve a
number of risks and uncertainties. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
foregoing, the words, "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will,"
"may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors
that could cause Hybridon's actual results to differ materially
from those indicated by such forward-looking statements, including
risks as to whether results obtained in preclinical studies or
early clinical trials, such as the results reported here, will be
indicative of results obtained in future preclinical studies or
clinical trials, or warrant further clinical trials and product
development; whether products based on Hybridon's technology will
advance through the clinical trial process and receive approval
from the United States Food and Drug Administration or equivalent
foreign regulatory agencies; whether, if such products receive
approval, they will be successfully distributed and marketed;
whether the patents and patent applications owned or licensed by
Hybridon will protect the Company's technology and prevent others
from infringing it; whether Hybridon's cash resources will be
sufficient to fund product development; and such other important
factors as are set forth under the caption "Risk Factors" in
Hybridon's Quarterly Report on Form 10-Q filed on May 10, 2005,
which important factors are incorporated herein by reference.
Hybridon disclaims any intention or obligation to update any
forward-looking statements. Contacts: MacDougall Biomedical
Hybridon, Inc. Communications 617-679-5500, x5526 508-647-0209 x12
Tim Sullivan Douglas MacDougall E-mail: Email: Georgetown
University Medical Center Amy DeMaria 202-687-5100 DATASOURCE:
Hybridon Inc. CONTACT: Tim Sullivan of Hybridon, Inc.,
+1-617-679-5500, ext. 5526, ; or Douglas MacDougall of MacDougall
Biomedical Communications, 508-647-0209 ext. 12, ; or Amy DeMaria
of Georgetown University Medical Center, +1-202-687-5100,
Copyright
Hybridon (AMEX:HBY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Hybridon (AMEX:HBY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024